Oncology Telemonitoring

Reimbursed by RIZIV-INAMI in Belgium since 1 January 2026. Healthentia lets your oncology team follow patients on oral anticancer therapy at home – with validated symptom reporting, graded alerts and one dashboard for the whole team.

Book a demo How it works
Patient at home checking her symptoms on her smartphone

The reimbursement framework

Who

Patients on oral anticancer therapy (Circular Omz. ZH 2026/04)

Start-up

€84.89 in month 1

Follow-up

Up to 4 × €59.89, months 2–5

Total

€324.45 per patient episode

How Healthentia Is Used

01

Enrol

The oncology nurse invites the patient at the start-up visit.

02

Report

Patients answer validated symptom questionnaires, with reminders and education.

03

Triage

Graded alerts and trends show the nurse who needs attention first.

04

Act

Call, adjust treatment or book a visit, and keep the GP informed.

Why Healthentia

  • Certified. EU MDR Class IIa medical device, validated at mHealthBelgium Level 3+.
  • Already reimbursed. In use under the RIZIV-INAMI heart-failure telemonitoring convention.
  • Built for the circular. Validated PROs, graded alerts, reminders, education, iOS, Android and web.
  • Saves nurse time. Urgent patients first; protocols configured per tumour type, without development.
  • Local. Belgian manufacturer and support team, based in Brussels.

Track Record

50
hospitals
12
countries
10,000
patients
35
publications
  • Oncology programmes with Gemelli (Rome): pancreatic, lung, ovarian, rectal and colorectal cancer
  • SUPERO study: average hospital stay cut from 6.03 to 2.12 days (n = 93)

Start oncology telemonitoring in 90 days

A pilot with 30–50 patients and your oncology nurse trained in a day.

Book a demo Heart failure